Related Experiment Videos
[Cyclosporin therapy for aplastic anemia].
S Nakao1, S Ohtake, S Shiobara
1Third Department of Medicine Kanazawa University School of Medicine.
[Rinsho Ketsueki] the Japanese Journal of Clinical Hematology
|September 1, 1990
Summary
Cyclosporin (CyA) shows promise for treating refractory aplastic anemia. Extended treatment durations and low doses may improve response rates in patients unresponsive to other therapies.
Area of Science:
- Hematology
- Immunology
Context:
- Aplastic anemia is a rare bone marrow failure disorder.
- Patients refractory to standard treatments pose a therapeutic challenge.
Purpose:
- To evaluate the efficacy and safety of cyclosporin (CyA) in patients with aplastic anemia unresponsive to conventional therapies.
Summary:
- Fourteen patients with refractory aplastic anemia received cyclosporin (CyA) for over four weeks.
- A 29% response rate (transfusion independence) was observed, with 50% of patients receiving CyA for over five weeks showing improvement.
- Treatment involved doses of 5-9 mg/kg/day, with responses appearing between 5-11 weeks. Common side effects like hirsutism and gingival hyperplasia were generally well-tolerated.
Impact:
- Cyclosporin (CyA) demonstrates potential as an effective treatment for refractory aplastic anemia.
- Long-term, low-dose CyA therapy may be crucial for achieving higher response rates in this patient population.